Heini, Alexander D

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 6.

Journal Article

Heini, Alexander D; Bacher, Ulrike; Pabst, Thomas (2024). Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL). British journal of haematology, 204(2), pp. 389-390. Wiley-Blackwell 10.1111/bjh.19195

Heini, Alexander D; Beck, Philipp; Bacher, Ulrike; Seipel, Katja; Zander, Thilo; Daskalakis, Michael; Pabst, Thomas (2023). BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom's Macroglobulinemia. Journal of Clinical Medicine, 12(6) MDPI 10.3390/jcm12062378

Heini, Alexander D; Bacher, Ulrike; Porret, Naomi; Wiedemann, Gertrud; Legros, Myriam; Stalder Zeerleder, Denise; Seipel, Katja; Novak, Urban; Daskalakis, Michael; Pabst, Thomas (2022). Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. Cells, 11(17) MDPI 10.3390/cells11172747

Heini, Alexander D; Bacher, Ulrike; Kronig, Marie-Noëlle; Wiedemann, Gertrud; Novak, Urban; Zeerleder, Sacha; Mansouri Taleghani, Behrouz; Daskalakis, Michael; Pabst, Thomas (2022). Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center. Bone marrow transplantation, 57(6), pp. 1010-1012. Springer Nature 10.1038/s41409-022-01658-x

Berger, Martin Dave; Heini, Alexander D; Seipel, Katja; Mueller, Beatrice; Angelillo-Scherrer, Anne; Pabst, Thomas (2017). Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. Hematological oncology, 35(4), pp. 789-796. Wiley 10.1002/hon.2307

Heini, Alexander D; Berger, Martin Dave; Seipel, Katja; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Novak, Urban; Pabst, Thomas (2017). Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years. Leukemia research, 53, pp. 28-34. Elsevier 10.1016/j.leukres.2016.12.001

This list was generated on Thu Mar 28 09:31:49 2024 CET.
Provide Feedback